Skip to main content

Table 2 COS treatment and embryo culture

From: The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles

Variables

uFSH

(n = 764)

rFSH-alfa

(n = 314)

P

Gn total dose (IU)

2334.5 ± 687.3

1912.3 ± 625.1

< 0.001

Oocytes retrieved

10.0 (6.8–14.0)

13.0 (8.0–17.0)

< 0.001

2PN oocytes

5.0 (3.0–8.0)

7.0 (4.0–11.0)

< 0.001

Transferrable embryos

4.0 (2.0–6.0)

5.0 (3.0–8.0)

< 0.001

High-quality embryos

3.0 (1.0–5.0)

4.0 (1.0–6.0)

< 0.001

OHSS

36 (4.7%)

22 (7.0%)

0.129

IVF/ICSI

  

0.014

 ICSI

118 (15.4%)

68 (21.7%)

 

 IVF

646 (84.6%)

246 (78.3%)

 

Number of embryo transfer cycles

  

< 0.001

 0

141 (18.5%)

32 (10.2%)

 

 1

408 (53.4%)

154 (49.0%)

 

 2

152 (19.9%)

90 (28.7%)

 

 3

57 (7.5%)

25 (8.0%)

 

 4

6 (0.8%)

10 (3.2%)

 

 5

0 (0.0%)

3 (1.0%)

 
  1. COS controlled ovarian stimulation; OHSS ovarian hyperstimulation syndrome; IVF in vitro fertilization; ICSI intracytoplasmic sperm injection; FSH follicle-stimulating hormone